Response to the letter by Uysal Tan and Tan regarding our article “short- and mid-term efficacy of sacral neuromodulation in the treatment of neurogenic overactive bladder in patients with multiple sclerosis”
Restricted accessLetterFirst published online October, 2025
Response to the letter by Uysal Tan and Tan regarding our article “short- and mid-term efficacy of sacral neuromodulation in the treatment of neurogenic overactive bladder in patients with multiple sclerosis”
PhéVChartier-KastlerEPanickerJN.Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol2016; 13: 275–288.
2.
GoudelockeCXavierKPechaB, et al. Evaluation of clinical performance and safety for the rechargeable InterStim Micro device in overactive bladder subjects: 6-month results from the global postmarket ELITE study. Neurourol Urodyn2023; 42: 761–769.
3.
DequirezP-LWachterSDBiardeauX.Sacral neuromodulation for low urinary tract dysfunction: Overview and mechanisms of action. Auton Neurosci Basic Clin2025; 261: 103337.
4.
OlivierLDequirezP-LCarolusB, et al. Short-term efficacy of sacral neuromodulation on cystometric parameters in patients with detrusor overactivity. Neuromodulation. Epub ahead of print 22 August 2025. DOI: 10.1016/j.neurom.2025.06.014.
5.
GroenendijkPMLycklamaàNyeholtAAHeesakkersJP, et al. Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence. BJU Int2008; 101(3): 325–329.
6.
BlokBFMGroenJBoschJLHR, et al. Different brain effects during chronic and acute sacral neuromodulation in urge incontinent patients with implanted neurostimulators. BJU Int2006; 98: 1238–1243.
7.
CruzFHerschornSAliottaP, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: A randomised, double-blind, placebo-controlled trial. Eur Urol2011; 60(4): 742–750.
8.
KendallHJKnopsAGerlachO, et al. Sacral neuromodulation in multiple sclerosis: The NEMISIS study. Eur Urol Focus. Epub ahead of print 3 March 2025. DOI: 10.1016/j.euf.2025.02.009.
